RxDoctor Payments Data

Michael Kelley, MD

Interventional Cardiology · Christiansburg, VANPI 1639251929

Payments from drug & device makers

$8,700in general payments, 2019–2025

Across 140 payments — averaging $62.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Inari Medical, Inc.$2K
  • Abbott$1K
  • Cardiovascular Systems Inc.$707
  • Penumbra, Inc.$368
  • Shockwave Medical, Inc$307
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$3,49640%
  • Food & beverage$5,19060%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,700 in reported general payments places this provider in the 60th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$181,645
Medicare patients
1,202
Services billed
2,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$250,189
BrilintaTicagrelor95$77,002
JardianceEmpagliflozin72$59,340
XareltoRivaroxaban68$56,730
Repatha SureclickEvolocumab35$30,962
EntrestoSacubitril/Valsartan31$27,378
Prasugrel Hcl60$11,267
Praluent PenAlirocumab13$10,190
Metoprolol Succinate374$4,401
Midodrine Hcl19$2,848
Ranolazine ErRanolazine44$2,633
Atorvastatin Calcium349$2,555
ClopidogrelClopidogrel Bisulfate275$2,162
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$1,577
Amlodipine Besylate257$1,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123$250,189210 claims
AstraZenecaBrilinta$62$77,00295 claims
Boehringer IngelheimJardiance$21$59,34072 claims
Johnson & JohnsonXarelto$295$56,73068 claims
NovartisEntresto$44$27,37831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Christiansburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →